Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 22, 2025.

via HealthDay

MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus dipeptidyl peptidase-4 inhibitors (DPP4is), according to a study published online July 22 in the Annals of Internal Medicine.

Kosuke Inoue, M.D., Ph.D., from Kyoto University in Japan, and colleagues compared the effect of GLP-1 RAs to DPP4is as second-line therapy for type 2 diabetes on the risk for dementia in a target trial emulation. Participants included Medicare fee-for-service beneficiaries aged 66 years or older who used metformin and initiated GLP-1 RAs or DPP4is between January 2017 and December 2018.

The analyses included 2,418 patients initiating GLP-1 RAs and 4,836 propensity score-matched patients initiating DPP4is (mean age, 71 years). The researchers found that during a median follow-up of 1.9 years, the outcome of dementia onset occurred in 96 and 217 patients in the GLP-1 RA and DPP4i groups, respectively. At 30 months, the estimated risk difference was −0.93 (95 percent confidence interval, −2.33 to 0.23) percentage points and the estimated risk ratio was 0.83 (95 percent confidence interval, 0.61 to 1.05). For those younger than 75 years and those 75 years and older, the estimated risk ratios were 0.64 (95 percent confidence interval, 0.46 to 0.93) and 1.22 (95 percent confidence interval, 0.74 to 1.66), respectively.

"Although there was a signal of lower incidence of dementia with GLP-1 RAs than with DPP4is among adults younger than 75 years, the causal relationship remains unclear," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-22 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords